



## Frontiers in Amyotrophic Lateral Sclerosis

Guest Editors:

**Prof. Dr. Mamede de Carvalho**

Faculty of Medicine-IMM,  
University of Lisbon, 1649-028  
Lisbon, Portugal

**Prof. Dr. Susanne Petri**

Department of Neurology,  
Hannover Medical School,  
Hannover, Germany

Deadline for manuscript  
submissions:

**closed (28 February 2022)**

### Message from the Guest Editors

Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder with a rapid functional decline and a short survival, but its progression rate has a large interindividual variability. The identification of biomarkers of disease progression would make it possible to improve clinical trials design and facilitate an easier identification of effective compounds. There is an extensive body of literature on neurophysiological, imaging, and neurochemical markers for investigating CSF and blood samples, cells, and tissues. Phosphorylated neurofilament heavy chain (pNfH) and the neurofilament light chain (NfL) are now considered as the most promising biomarkers. However, investigators persist in a continuous effort to find other biomarkers, as demonstrated by the emerging literature on chitinases in ALS. The impact of these different markers on clinical trials depends on their predictive value for disease outcome. In this Special Issue we intended to collect original contributions on novel markers of disease progression and related outcomes, in the perspective of their potential interest for clinical trials.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Stephen D. Meriney

Department of Neuroscience,  
University of Pittsburgh,  
Pittsburgh, PA 15260, USA

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYINDEX, CAPlus / SciFinder, and other databases.

**Rapid Publication:** manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the second half of 2023).

## Contact Us

Brain Sciences Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/brainsci](http://mdpi.com/journal/brainsci)  
[brainsci@mdpi.com](mailto:brainsci@mdpi.com)  
[X@BrainSci\\_MDPI](https://twitter.com/BrainSci_MDPI)